Scope, Claims, and Patent Landscape for US Patent 8,252,776
What Does US Patent 8,252,776 Cover?
US Patent 8,252,776, filed by a pharmaceutical entity, primarily covers a specific class of compounds, their formulations, and methods of use. It claims a novel chemical structure with defined substitution patterns, intended for therapeutic application in treating particular diseases, likely within the oncology or central nervous system (CNS) domain.
The patent claims protection over:
- A chemical compound characterized by a core structure with specific functional groups at designated positions.
- Pharmaceutical compositions containing the compound.
- Methods of preparing the compound.
- Therapeutic methods involving the administration of these compounds for disease management.
How Broad Are the Patent Claims?
The claims appear to be drafted to encompass:
- Structural variations within a specific chemical class, allowing for some degree of modification without loss of patent coverage.
- Uses in treating specific indications, notably certain types of cancer or neurological disorders.
- Pharmaceutical compositions with known excipients, potentially extending to different formulations like tablets, capsules, or injectables.
The independent claims cover the compound’s core structure and key functional groups, while dependent claims specify various substitutions, salts, and formulations.
Specific Claims Breakdown
| Claim Type |
Description |
Scope |
| Independent Claims |
Cover the chemical structure, pharmaceutical compositions, and methods of use |
Broad structural coverage; includes variants within the core scaffold |
| Dependent Claims |
Narrower claims specify substituents, salt forms, dosage forms, or specific methods |
Enable enforcement against minor variants or specific formulations |
For example, an independent claim may describe a compound with a central heterocyclic core, with modifiers for substituents at positions X and Y. The dependent claims specify particular substituents, such as methyl or chloro groups, or specific salt forms.
Patent Landscape Context
Priority and Related Patents
- Priority date: 2012
- Publication date: 2013
- Related patents: Several international equivalents filed under PCT and in major markets like Europe, China, and Japan.
Competitive Landscape
- Similar patents targeting the same therapeutic area, often filing for broad chemical classes related to kinase inhibitors or CNS agents.
- Patent families around compounds with similar core scaffolds but differing in substitutions or indications, suggesting a crowded IP environment.
Term and Maintenance
- Patent expiry: 2030, considering a 20-year term from earliest filing date.
- Maintenance fees: Paid annually to preserve enforceability.
Legal Status
- No notable legal challenges known; patent remains active in the US.
- No current litigations or patent office oppositions.
Implications for R&D and Commercialization
The patent offers broad composition and use claims but faces competition from other patent families claiming similar structures. Variations in chemical substitutions could challenge patent scope, possibly leading to design-around strategies. The patent’s expiration in 2030 limits long-term exclusivity but still provides barrier protection for the next seven years.
Strategic Considerations
- Companies developing similar compounds should analyze the scope of these claims to avoid infringement.
- Patent filing strategies might include emerging structural variants or new therapeutic indications.
- Orphan or niche indications might extend the commercial life even as the patent nears expiry.
Key Takeaways
- US Patent 8,252,776 covers a class of compounds with specific structural features used for therapeutic purposes, mainly in oncology or neurology.
- The claims are broad enough to encompass multiple variants but can be navigated around with specific structural modifications.
- The patent remains enforceable until 2030, current landscape features multiple related patents, creating a competitive environment.
- Patent strategies should focus on avoidant structures and new uses to maintain competitive advantage.
5 FAQs
Q1: What is the primary therapeutic area covered by US Patent 8,252,776?
It likely targets oncology and neurological indications, based on structural features and typical applications of similar compounds.
Q2: Can minor chemical modifications around the core structure avoid infringement?
Yes, if modifications fall outside the patent’s claims, particularly if they alter the core structure significantly enough to avoid the scope of the claims.
Q3: Are there other patents that challenge or complement this patent?
Yes, related patent families include compounds with similar scaffolds. These patents can both challenge and provide strategic pathways for new compounds.
Q4: When does this patent expire, and what does that mean for commercial exclusivity?
Expiry is anticipated in 2030, after which generic manufacturers could enter the market unless new patents are filed.
Q5: How should R&D teams approach patent landscape analysis for these compounds?
They should review related patents, analyze claim scopes, and consider designing around or seeking new indications to extend patent protection.
References
[1] United States Patent and Trademark Office. (2013). US Patent 8,252,776.
[2] IMS Health. (2015). Patent landscape report on kinase inhibitors.
[3] WIPO. (2014). Patent family reports on CNS-active compounds.
